39876-39-6

Basic information

• Product Name: 8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE
• Synonyms: 8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole(SALTDATA: FREE);6-FLUORO-1,2,3,4-TETRAHYDROPYRIDO(4,3-B)INDOLE;8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE;AKOS JY2082799;Fluoro-1,2,3,4-tetrahydropyrido[4,3]indole;6-Fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indole 97%;6-Fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indole97%;8-FLUORO-2,3,4,5-TETRAHYDROPYRIDO(4,3-B)INDOLE
• CAS NO: 39876-39-6
• Molecular Formula: C₁₁H₁₁FN₂
• Molecular Weight: 190.22
• Mol File: 39876-39-6.mol

Chemical Properties

• Melting Point: 214-216°C
• Boiling Point: 355.1 °C at 760 mmHg
• Flash Point: 168.5 °C
• Appearance: /
• Density: 1.277 g/cm³
• Vapor Pressure: 3.21E-05mmHg at 25°C
• Refractive Index: 1.645
• PKA: 16.93±0.20(Predicted)
• CAS DataBase Reference: 8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE(39876-39-6)
• EPA Substance Registry System: 8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE(39876-39-6)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 39876-39-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE is used as a serotonin receptor agonist for the development of new drugs targeting psychiatric disorders. Its unique structure and pharmacological activity make it a valuable compound for research and development in the field of medicinal chemistry.
Used in Psychiatric Disorders Treatment:
8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE is used as a potential therapeutic agent for the treatment of psychiatric disorders, including depression and anxiety. Its agonistic effect on serotonin receptors may contribute to the modulation of mood and emotional regulation, offering a new approach to managing these conditions.
Used in Medicinal Chemistry Research:
8-FLUORO-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE is used as a research target for the development of improved drugs with enhanced efficacy and reduced side effects. Its fluorinated derivative nature and indole alkaloid family membership provide a unique platform for exploring the structure-activity relationship and optimizing drug candidates for better therapeutic outcomes.

InChI:InChI=1/C11H11FN2/c12-7-1-2-10-8(5-7)9-6-13-4-3-11(9)14-10/h1-2,5,13-14H,3-4,6H2

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 371-14-2 4-fluorophenylhydrazine 
• 870471-42-4 8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylic acid tert-butyl ester 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 41979-39-9 4-piperidone hydrochloride 
• 58038-66-7 2-carbethoxy-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido<4,3-b>indole 

Downstream Products

• 136725-26-3 1-Trityl-4-(8-fluoro-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-2-ylmethyl)piperidine 

Relevant articles and documents

NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Aryl substituted aminotetrahydropyran compound and use thereof

The invention relates to an aryl substituted aminotetrahydropyran compound and use thereof, and further relates to a pharmaceutical composition comprising the compound. The compound or pharmaceuticalcomposition provided by the invention can be used as a dipeptidyl peptidase-IV (DPP-IV) inhibitor.

1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.

(1 R,2 R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3- b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A potent and highly selective cathepsin k inhibitor for the treatment of osteoarthritis

Directed screening of nitrile compounds revealed 3 as a highly potent cathepsin K inhibitor but with cathepsin S activity and very poor stability to microsomes. Synthesis of compounds with reduced molecular complexity, such as 7, revealed key SAR and demonstrated that baseline physical properties and in vitro stability were in fact excellent for this series. The tricycle carboline P3 unit was discovered by hypothesis-based design using existing structural information. Optimization using small substituents, knowledge from matched molecular pairs, and control of lipophilicity yielded compounds very close to the desired profile, of which 34 (AZD4996) was selected on the basis of pharmacokinetic profile.

Synthesis and structure-activity relationships of γ-carboline derivatives as potent and selective cysLT1 antagonists

A γ-carboline series of cysLT1 receptor antagonists has been prepared. Some of the compounds show good potencies both, in vitro and in vivo, compared to the standard compounds.

Heterocyclic derivatives, their preparation and medicinal products containing them

Compounds are disclosed of formula: in which R1 represents a residue of formula STR1 X represents a hydrogen atom or an alkyl radical, Y represents a hydrogen atom or an alkyl or alkoxy radical, Z represents an alkyl radical, n is equal to 2 or 3, Het represents a substituted piperidino (substituted at the 4-position with a 1-indenylidene, 1-indenyl or 1-indanyl radical or with a chain --(CH2)m --R2 or =CH--R2), substituted 1,2,3,6-tetrahydro-1-pyridyl (substituted at the 4-position with a chain --(CH2)m --R2), m is equal to 1 or 2, and R2 represents an optionally substituted 2- or 3-indolyl radical, a 1- or 2-indanyl, 1- or 2-indenyl, an optionally substituted 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-2-yl radical, a 1,2,3,4-tetrahydro-3-quinolyl radical, an optionally substituted 1,2,3,4-tetrahydro-2-naphthyl radical or a 1-indolyl radical, their preparation and medicinal products containing them.

Antipsychotic Activity of Substituted γ-Carbolines

Several novel substituted γ-carbolines were synthesized and examined in a series of in vitro and in vivo pharmacological tests to determine potential antipsychotic activity.Most compounds were orally active in blocking the conditioned avoidance response (CAR) in rats but did not antagonize apomorphine-induced stereotyped behavior.Compound 17 (Wy-47,384), a γ-carboline with a 3-(3-pyridinyl)propyl side chain, was selected for development as an atypical antipsychotic agent because of its potent and selective profile in preclinical psychopharmacological tests.It blocked CAR in rats with an AB50 of 14 mg/kg po, showed weak affinity for the D2 receptor site (Ki = 104 nM), and showed differential potency in antagonizing apomorphine-induced stereotyped behavior (ED50 = 11 mg/kg ip) and climbing behavior (ED50 = 4 mg/kg ip).Such activities are suggestive of antipsychotic efficacy combined with a low potential for extrapyramidal side effect (EPS) liability.